Fund Name

$ Value

% Port.

COM NEW

COMMON STOCK

$ Bought

% Increased

% Reduced

$ Sold

Shares

Percent

Date

Type

% Portfolio

% Chg

$ Change

$ Held

# Shares

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for individuals living with anxiety, depression, and other central nervous system (CNS) disorders. The company's pipeline includes six clinical stage product candidates, including five investigational agents belonging to drugs known as pherines. Its product pipeline comprises PH94B, a fasedienol nasal spray, which is in Phase III development for the treatment of social anxiety disorder; and PH10, a Ituvone nasal spray which is in Phase II development for the treatment of major depressive disorder. In addition, the company is also developing PH15, an early-stage investigational synthetic neuroactive steroid for the treatment of cognition improvement; PH80, an odorless and tasteless synthetic investigational pherine for the treatment of menopausal hot flashes and migraine; PH284, an early-stage investigational synthetic neuroactive steroid for the treatment of wasting syndrome Cachexia; and AV-101, an oral nmdr glycine site antagonist for depression and neurological disorders. Further, it has a license and collaboration agreement with EverInsight Therapeutics Inc. to develop and commercialize to address ophthalmologic and CNS disorders. The company was founded in 1998 and is headquartered in South San Francisco, California.

Vistagen Therapeutics, Inc., a late clinical-stage biopharmaceutical company, primarily focus to transform the treatment landscape for ind...

Datesorted ascending	Fund Name	Type	% Portfolio	% Chg	$ Change	$ Held	# Shares
2023-02-15	PERSONAL CAPITAL ADVISORS CORP	NEW	Premium	Premium	Premium	Premium	903
2022-11-15	Pinz Capital Management, LP	SOLD OFF	Premium	Premium	Premium	Premium	-
2022-05-16	Amalgamated Financial Corp.	NEW	Premium	Premium	Premium	Premium	30,350
2022-05-16	Parametric Portfolio Associates LLC	REDUCED	Premium	Premium	Premium	Premium	13,029
2021-08-13	QS Investors, LLC	NEW	Premium	Premium	Premium	Premium	177,900

Fund Name	# Shares	$ Value	% Port.
QS Investors, LLC	177,900	561,000	0.01%
Amalgamated Financial Corp.	30,350	38,000	-
Parametric Portfolio Associates LLC	13,029	16,000	-
PERSONAL CAPITAL ADVISORS CORP	903	2,791	-
Pinz Capital Management, LP	-	-	-

Fund Name	$ Value	% Port.
QS Investors, LLC	561,000	0.01%
Amalgamated Financial Corp.	38,000	-
Parametric Portfolio Associates LLC	16,000	-
PERSONAL CAPITAL ADVISORS CORP	2,791	-
Pinz Capital Management, LP	-	-

Fund Name	$ Bought
QS Investors, LLC	561,000
Amalgamated Financial Corp.	38,000
PERSONAL CAPITAL ADVISORS CORP	2,791

VTGN - VistaGen Therapeutics Inc Stock Price, Fair Value and News

Which funds bought or sold VTGN recently?

Which funds are the top buyers of VTGN?

Which funds have put a big percent of portfolio in VTGN?

Trend of No. of funds that hold VTGN

Changes in Positions

Investor Breakout

Investor Churn (# Increased Holdings)

New Buys

Reductions

Sold off